SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Howard Hoffman who wrote (836)5/9/1997 9:51:00 PM
From: Brad C. Dunlap   of 1762
 
Hi Howard, supposedly the Clinton oncology initiative is suppose to approve/disapprove all cancer drugs within 6 months of their filings. Since Idec filed the end of Feb. and announced the filing the beginning of March, we're looking around the end of August beginning of Sept at the latest. The FDA pannel meeting is scheduled for the end of July. I believe the Cephalon situation was somewhat expected every since CEPH stock dropped from 40 to 20 in the beginning of 1996 when the European study showed that more patients died form the drug then the placebo. I realize there were high expectations from mangement but it was common knowledge that it was going to be a battle. A much different situation then Idec's.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News